Neoantigen Cancer Vaccine Helps BioNTech Advance Oncology Ambitions
Encouraging 50% Response Rate
After many years of failures and setbacks, neoantigen-targeting immunotherapies are gaining momentum, with BioNTech and Roche among the frontrunners.
You may also be interested in...
CAR-T has revolutionized the treatment options for blood cancers but its application for solid tumors has fallen short. The German biotech hopes that by combining a CAR-T cell therapy with an mRNA vaccine could be a gamechanger.
Hopes rise as first four evaluable patients experienced no serious adverse events, and a sustained decline in level of key Huntington’s disease protein with the novel gene therapy product.
The UK company did not profit greatly from its role in COVID-19 vaccine, Vaxzevria, but hopes the same technology can form part of a breakthrough in hepatitis B.